SNA-60-367, New Peptide Enzyme
Inhibitors against Aromatase Sir: In the course of our screening program for new aromatase inhibitors, we have isolated new plipastatin1~3) group peptide enzyme inhibitors from the broth of soil bacterium SNA-60-367. This report is concerned with the isolation, structures and biological properties of these novel enzyme inhibitors. The producing microorganism was cultivated at 27°C for 120 hours (final pH 8.4) in a 500ml volume Erlenmeyer flask containing 70ml of the medium composed of glucose 2%, soluble starch 1%, meat extract 0.1%, dried yeast 0.4%, soybean flour 2.5%, NaCl 0.2%, and K2HPO40.005%, adjusted to pH 6.7. The active material was extracted into butanol from both the filtered broth (4.7 liter) and the aqueous acetone extract of the mycelium. The butanol layer was evaporated and the extract was suspended in water. It was extracted with ethyl acetate and the water layer was subjected to a MCI GEL CHP 20P (Mitsubishi Chemical Industries, 1.4 x 20cm). After washing with water and 50% MeOHfor removing impurities, the active material was eluted with MeOH. The eluate was subjected to silica gel column (Merck, 70~230 mesh, 3.6x 50cm) The UV, IR, XH and 13C NMRspectra of these compoundssuggested that they were peptide enzyme inhibitors.
A typical UV spectrum of SNA-60-367-13 in MeOHand 13C NMRspectrum in DMSO-d6are shown in Figs. 1 and 2 . Thus, all compounds were hydrolyzed 529 by 6n HC1 at 110°C for 24 hours and Thr(l), Glu(3), Tyr(2), Pro(l) and Orn(l) were detected as common components of all of the SNA-60-367 compounds. In the 3 molecules of Glu, 1 molecule was identified Gin by using FAB-MSand linked scan spectra. Some of the amino acids, He, Val, Ala and amino butyric acid (Aba), were observed as variable components in each compound as shown in Fig. 3 . HRFAB-MS and the elemental composition data of the 17 compounds are shown in Table 1 . These results suggested that SNA-60-367 compounds were plipastatin group enzyme inhibitors which were reported as phospholipase A2 inhibitors. The structures of the peptide part were determined by using FAB-MS and linked scan spectra. Structures offatty acid moieties were determined by using EI-MS of the fatty acid methyl esters and negative FAB/linked scan spectra of the intact compoundswith the analyses of the charge remote fragmentations. From these data, structures of SNA-60-367 compounds are listed in Fig. 3 . SNA-60-367-3, 6, 7 and 12 were identical with plipastatins,Al5
A2, Bx and B2, respectively. Retention time ofå SNA-60-367-3 and 6 were in accord with authentic samples on HPLC.The rest of compoundswere new substances different in their the amino acids composition and fatty acid structure compared to the known plipastatins. Detailed mass spectrometric analyses of the structures will be reported elsewhere. Inhibition activity against human placental aromatase was measured by the same method as described previously4). Inhibition % of the compounds at 100fig/ml were shown to be between 30% to 80% as listed activity at approximately 50 times greater potency (1 to 3/xm)1} than the aromatase activity reported here. But the structural similarity ofaromatase substrate (androstenedione) and these compounds was not recognized. This is the first report to show that the peptide enzyme inhibitors, plipastatins, inhibit human aromatase activity. Weare now interested in the inhibition mechanism of these compoundsagainst aromatase. Antimicrobial in zone (30 jitg/disc).
